February 2013, Year V, n. 2
Claudio Jommi
Managing healthcare spending in the age of Austerity: better value for money is what we need.
Telos: Contrasting the decline of the manufacturing sector is widely felt as a priority. Biomedical and pharmaceutical research might be one of the pillars of an innovation-driven growth pattern. What are in your view the most effective incentives for research and development at the national level? To what extent does the localisation of investments respond to the efficiency of the institutional framework (certainty and stability of the rules, synergies between Universities and the industry), to the reimbursement price of pharmaceuticals or to other aspects?
Claudio Jommi: It is important to make a clear distinction between research and pre-clinical development on one side, and clinical development on the other side. Tax incentives and subsidies are very important tools to encourage research and pre-clinical development, as is any initiative stimulating technology transfer, facilitating the relations between Universities/other research centres and the industry, improving a transparent and merit-driven allocation of funds for public research ... more
Editorial
The story of innovation in healthcare may be told in many ways. A scientist will describe innovation as a triumphal march towards the emancipation of men from illness: a series of breakthrough discoveries and small incremental improvements, inevitably leading to better life and health conditions for the population ... more
SocialTelos